Cheshire Michael D, Akbar Usman A
Internal Medicine/Clinical Lipidology, West Virginia University School of Medicine, Parkersburg, USA.
Internal Medicine, West Virginia University School of Medicine, Parkersburg, USA.
Cureus. 2024 Aug 30;16(8):e68198. doi: 10.7759/cureus.68198. eCollection 2024 Aug.
There was an unprecedented increase in cardiovascular mortality during the 20th century, which ultimately led to a deeper understanding of cholesterol and its role in cardiovascular disease. Akira Endo is a medical innovator who sought to change the tide of this epidemic. He is often referred to as the "Father of Statins" because of his identification of the first 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) inhibitor, which fostered a new era in cholesterol treatment. The offspring of this discovery - statin medications - changed the landscape of cardiovascular prevention and improved outcomes for millions of patients across the globe. Arika Endo used his prior research experience in biochemistry and fungi to create a new way to meet the objective of reducing cardiovascular morbidity and mortality. In this way, he should be recognized not only for this discovery of statins but as a role model for researchers at any stage of their careers.
20世纪心血管疾病死亡率出现了前所未有的增长,这最终促使人们对胆固醇及其在心血管疾病中的作用有了更深入的了解。远藤章是一位医学创新者,他试图改变这一流行病的趋势。由于他发现了第一种3-羟基-3-甲基戊二酰辅酶A(HMG-CoA)抑制剂,他常被称为“他汀类药物之父”,这开创了胆固醇治疗的新时代。这一发现的成果——他汀类药物——改变了心血管疾病预防的格局,改善了全球数百万患者的治疗效果。远藤章利用他先前在生物化学和真菌方面的研究经验,创造了一种新方法来实现降低心血管疾病发病率和死亡率的目标。通过这种方式,他不仅应因其对他汀类药物的发现而受到认可,还应成为处于职业生涯任何阶段的研究人员的榜样。